Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-03-29
2011-03-29
Kosack, Joseph R (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S456000, C548S525000, C549S399000
Reexamination Certificate
active
07915301
ABSTRACT:
The present invention relates to novel compounds for the inhibition of cyclin-dependent kinases, and more particularly, to chromenone derivatives of formula (Ia),wherein R1, R2, R3, R4, R5, R6, R7and A have the meanings indicated in the claims. The invention also relates to processes for the preparation of the compounds of formula (Ia), to methods of inhibiting cyclin-dependent kinases and of inhibiting cell proliferation, to the use of the compounds of formula (Ia) in the treatment and prophylaxis of diseases, which can be treated or prevented by the inhibition of cyclin-dependent kinases such as cancer, to the use of the compounds of formula (Ia) in the preparation of medicaments to be applied in such diseases. The invention further relates to compositions containing a compound of formula (Ia) either alone or in combination with another active agent, in admixture or otherwise in association with an inert carrier, in particular pharmaceutical compositions containing a compound of formula (Ia) either alone or in combination with another active agent, together with pharmaceutically acceptable carrier substances and auxiliary substances.
REFERENCES:
patent: 4900727 (1990-02-01), Kattige et al.
patent: 5116954 (1992-05-01), Briet et al.
patent: 5284856 (1994-02-01), Naik et al.
patent: H1427 (1995-04-01), Briet et al.
patent: 5723313 (1998-03-01), Sherr et al.
patent: 5733920 (1998-03-01), Mansuri et al.
patent: 5849733 (1998-12-01), Kim
patent: 6699854 (2004-03-01), Wang et al.
patent: 7056942 (2006-06-01), Hildesheim et al.
patent: WO 01/83469 (2001-11-01), None
patent: WO 2004-004632 (2004-01-01), None
patent: WO 2007-148158 (2007-12-01), None
Davies et al. “Structure-based design of cyclin-dependent kinase inhibitors” Pharmacology & Therapeutics, 2002, pp. 125-133.
Toogood, Peter “Cyclin-Dependent Kinase Inhibitors for Treating Cancer” Medicinal Research Reviews, 2001, pp. 487-498.
PLATINOL-AQ (cisplatin injection) package insert. Revised Apr. 2006.
Taxol Injection package insert. Revised Jul. 2007.
Ortega et al., Cyclin D-dependent kinases, INK4 inhibitors and cancer, Biochimica et Biophysica Acta 1602, 2002, pp. 73-87.
Kelland, Expert Opinion on Investigational Drugs, 2000, vol. 9, No. 12, pp. 2903-2911, Ashley Publications Ltd., ISSN: 1354-3784.
Elsayed et al., Selected Novel Anticaner Treatments Targeting Cell Signaling Proteins, The Oncologist, 2001, vol. 6, pp. 517-537.
Parker et al., Blood, Jan. 15, 1998, vol. 91, No. 2, pp. 458-465.
Stadler et al., Jounal of Clinical Oncology, Jan. 2000, vol. 18, No. 2, pp. 371-375.
Patel et al., Journal of Clinical Investigation, Nov. 1998, vol. 102, No. 9, pp. 1674-1681.
Shapiro et al., Clinical Cancer Research, Jun. 2001, vol. 7, pp. 1590-1599.
Senderowicz et al., Journal of National Cancer Institute, Mar. 1, 2000, vol. 92, No. 5, pp. 376-387.
Perez-Roger et al., Current Pharmaceutical Biotechnology, 2000, vol. 1, pp. 107-116, Bentham Science Publishers ltd.
Senderowicz, Oncogene, 2000, vol. 19, pp. 6600-6606, Macmillan Publishers Ltd.
Soni et al.; Journal of the National Cancer Institute (2001), 93(6), 436-446.
Zhang et al.; Cancer Research 57: (1997); 169-175.
Ortega et al; Biochimica et Biophysica Acta 1602 (2002) 73-87.
Wei et al.; Int. J. Cancer: 80, 199-204 (1999); UICC; Wiley-Liss Inc.
Elsayed et al.; The Oncologist, (2001); 6:517-537.
Kohzato et al.; Hepatology Research (2001), 21(1), 27-39 (Abstract only).
Dong Y. et al.; Anticancer Research (2001), 21(1A), 103-108 (Abstract only).
Li JQ et al.; Human Pathology (2001), 32(9), 945-953 (Abstract only).
Naik et al., Tetrahedron, vol. 44., No. 7, (1988) p. 2081-2086, Great Britain, XP002093909.
Ghosh et al., Tetrahedron: Asymmetry, (1998), vol. 9, p. 1-45.
Barnes et al., J. Am. Chem. Soc., 2002, 124 (44), 13097-13105.
Dorland's Pocket Medical Dictionary, publ. W.B. Saunders Co., p. 350 (1989).
The American College Dictionary, publ. Random House, p. 756 (1967).
Senderowicz et al, “Preclinical and Clinical Development of Cyclin-Dependent Kinease Modulators,” J. Natl. Cancer Institute, 2000, 376-387.
Naik et al, “An Anti-Inflammatory Cum Immunomodulatory Piperidinylbenzopyranone fromDyoxylum Binectariferum: Isolation, Structure and Total Synthesis”; Tetrahedron, 1998, 44(7), 2081-2086.
Pérez-Roger et al, “Inhibition of Cellular Proliferation by Drug Targeting of Cyclin-Dependent Kinases”; Curr. Pharm. Biotechnol, Jul. 1, 2000(1), 107-116.
Losiewocz et al, “Potent Inhibition of CDC2 Kinase Activity by the Flavonoid L86-8275”; Biochemical and Biophysical Research Communications, 1994, 589-595.
J. Org Chem. 1992, 57, 6321-6323.
Larget et al, “Convenient Extension of the Wessely-Moser Rearrangement for the synthesis of Substituted Alkylaminoflavones as Neuroprotective Agents in Vitro”; Bioorganica and Medicinal Chemistry Letters 10 (2000) 835-838.
Tsuritani et al; Organic Letters 2001, vol. 3, No. 17, 2709-2711.
Bang-Chi-Chen et al, “A New Facile Method for the Synthesis of 1-Arylimidazoles-5-Carboxylates”, Tetrahedron Letters 41 (2000) 5453-5456.
Falb et al, “A Convenient Synthesis of Chiral Oxazolidin-2-Ones and Thiazolidin-2-Ones and an Improved Preparation of Triphosgene”; Synthetic Communications, 23(20), 2839-2844, 1993.
Hosoi et al, J. Biochem 117, 741-749 (1995).
Ongkeko et al, “Inactivation of CDC2 Increases the Level of Apoptosis Induced by DNA Damage”; Journal of Cell Science 108, 2897-2904, 1995.
Schwartz et al, “Phase I Study of Cyclin-Dependent Kinase Inhibitor Flavopiridol in Comination with Paclitaxel in Patients with Advanced Solid Tumors”, 2002.
Tan et al, “Phase I Clinical and Pharmacokinetic Study of Flavopiridol Administered as a Daily 1-Hour Infusion in Patients with Advanced Neoplasms”, Journal of Clinical Oncology, vol. 20, No. 19, Oct. 1, 2002, pp. 4074-4082.
Hirama et al, Blood, “Role of the Cyclin-Dependent Kinase Inhibitors in the Development of Cancer”, The Journal of the American Society of Hematology, Aug. 1, 1995, Blood, vol. 88, No. 3, Aug. 1, 1995, pp. 841-854.
Edward A. Sausville, “Cyclin-Dependent Kinases: Novel Targets for Cancer Treatment”, Developmental Therapeutics Program, pp. 9-21, 1999.
Elsayed et al, “Selected Novel Anticancer Treatments Targeting Cell Signaling Proteins”,The Oncologist; 2001; 6: pp. 517-537.
Meier et al, “Properties and Potential Applications of Chemical Inhibitors of Cyclin-Dependent Kinases”, Pharmacol, Ther., vol. 82, Nos. 2-3, pp. 279-284, 1999.
Sausville et al, “Cyclin-Dependent Kinases: Initial Approaches to Exploit a Novel Therapeutic Target”, Pharmacol, Ther. vol. 82, Nos. 2-3, pp. 285-292, 1999.
Parker et al, “Early Induction of Apoptosis in Hematopoieti Cells Lines After Exposure to Flavopiridol”, The American Society of Hematology, Blood, vol. 91, No. 2, Jan. 15, 1998; pp. 458-465.
Davies et al., “Structure-Base Design of Cyclin-Dependent Kinase Inhibitors,” Pharmacology & Therapeutics, 2002, pp. 125-133.
Toogood, Peter, “Cyclin-Dependent Kinase Inhibitors for Treating Cancer,” Medicinal Research Reviews, 2001, pp. 487-498.
Bristol-Myers Squibb Patient Information for Taxol, Mar. 2003.
Schwartz et al., “Phase I Study of the Cyclin-Dependent Kinase Inhibitor Flavopiridol in Comination with Paclitaxel in Patients with Advanced Solid Tumors,” Journal of Clinical Oncology, vol. 20, No. 8, pp. 2157-2170; 2002.
Hirama et al., “Role of the Cyclin-Dependent Kinase Inhibitors in the Development of Cancer,” Blood, 1995, vol. 86, No. 3, pp. 841-854.
Gross et al., “A Stereocontrolled approach to Substituted piperidones and piperidines; Flavopiridol D-ring analog,” Tetrahedron Letters 42, 2001, pp. 1631-1633.
Joshi Kalpana
Joshi Rajendrakumar
Kamble Shrikant
Kulkarni Sanjeev
Lal Bansi
Frommer Lawrence & Haug
Kosack Joseph R
Piramal Life Science Limited
LandOfFree
Inhibitors of cyclin dependent kinases and their use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of cyclin dependent kinases and their use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of cyclin dependent kinases and their use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2674390